Trastuzumab
- Generic Name
- Trastuzumab
- Brand Names
- Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ontruzant, Perjeta-Herceptin, Phesgo, Trazimera, Herwenda, Ogivri, Zercepac, Tuznue
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 180288-69-1
- Unique Ingredient Identifier
- P188ANX8CK
- Background
Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic bre...
- Indication
For the adjuvant treatment of HER2-overexpressing breast cancer, trastuzumab is indicated in several clinical settings: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; as part of a treatment regimen with docetaxel and carboplatin; or as monotherapy following multi-modality anthracycline-based th...
- Associated Conditions
- Breast Cancer, Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Adenocarcinoma of the Stomach, Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage I Breast Cancer
- Associated Therapies
- -
Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Cinnagen
- Target Recruit Count
- 214
- Registration Number
- NCT04957212
- Locations
- 🇮🇷
Qaem Hospital, Mashhad, Khorasan Razavi, Iran, Islamic Republic of
🇮🇷Amir Hospital, Shiraz, Iran, Islamic Republic of
🇮🇷Shahid Faghihi Hospital, Shiraz, Iran, Islamic Republic of
Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy
- First Posted Date
- 2021-06-16
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 50
- Registration Number
- NCT04928261
- Locations
- 🇨🇦
The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Shanghai Henlius Biotech
- Target Recruit Count
- 150
- Registration Number
- NCT04908813
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, China
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
- Conditions
- Interventions
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Ruth O'Regan
- Target Recruit Count
- 48
- Registration Number
- NCT04886531
- Locations
- 🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States
🇺🇸University of Wisconsin, Madison, Wisconsin, United States
🇺🇸University of Rochester Medical Center, Rochester, New York, United States
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
- Conditions
- Interventions
- First Posted Date
- 2021-05-05
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1150
- Registration Number
- NCT04873362
- Locations
- 🇺🇸
Alabama Oncology, Alabaster, Alabama, United States
🇺🇸Roy and Patricia Disney Family Cancer Center- Providence Saint Joseph Medical Center, Burbank, California, United States
🇺🇸Innovation Clinical Research Institute, Cerritos, California, United States
Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC
- Conditions
- Interventions
- First Posted Date
- 2021-03-29
- Last Posted Date
- 2023-04-25
- Target Recruit Count
- 67
- Registration Number
- NCT04819971
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Tucatinib Together With Pembrolizumab and Trastuzumab
- Conditions
- Interventions
- First Posted Date
- 2021-03-09
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Breast Cancer Trials, Australia and New Zealand
- Target Recruit Count
- 57
- Registration Number
- NCT04789096
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Parkville, Victoria, Australia
🇦🇺Macquarie University, Macquarie Park, New South Wales, Australia
🇦🇺Nepean Cancer Care Centre, Kingswood, New South Wales, Australia
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
- Conditions
- Interventions
- First Posted Date
- 2021-03-05
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1157
- Registration Number
- NCT04784715
- Locations
- 🇬🇧
Research Site, Taunton, United Kingdom
TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)
- Conditions
- Interventions
- First Posted Date
- 2021-02-18
- Last Posted Date
- 2021-06-02
- Target Recruit Count
- 120
- Registration Number
- NCT04760431
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China
🇨🇳Peking University International Hospital, Beijing, Beijing, China
Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2021-06-04
- Target Recruit Count
- 60
- Registration Number
- NCT04717531
- Locations
- 🇨🇳
the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.